The BRAFV600E mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome

Thyroid

Volumn 24, Issue 8, 2014, Pages 1267-1274

  Russo, Marco ^a   Malandrino, Pasqualino ^a   Nicolosi, Maria Luisa ^a   Manusia, Mario ^b   Marturano, Ilenia ^a   Trovato, Maria Antonietta ^b   Pellegriti, Gabriella ^a   Frasca, Francesco ^a   Vigneri, Riccardo ^a,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b Garibaldi Nesima Hospital   (Italy)

^c Humanitas Catania Oncology Centre   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; THYROGLOBULIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THYROID CARCINOMA; THYROIDECTOMY; UTERINE CERVIX CARCINOMA; BLOOD; CARCINOMA; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDY; THYROID TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 84904690611     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0675     Document Type: Article

References (52)

1. Ito Y, Nikiforov YE, Schlumberger M, Vigneri R 2013 Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol 9:178-184.
2. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
3. Leenhardt L, Grosclaude P, Cherie-Challine L; Thyroid Cancer Committee 2004 Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056-1060. (Pubitemid 40076130)
4. Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E, Devesa SS 2013 Follicular thyroid cancer incidence patterns in the United States, 1980-2009. Thyroid 23:1015-1021.
5. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R 2013 Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:965212.
6. Yoo F, Chaikhoutdinov I, Mitzner R, Liao J, Goldenberg D 2013 Characteristics of incidentally discovered thyroid cancer. JAMA Otolaryngol Head Neck Surg 139:1181-1186.
7. Boyle P, Ferlay J 2005 Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488. (Pubitemid 40458328)
8. Agate L, Lorusso L, Elisei R 2012 New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest 35:3-9.
9. Sherman S, Fagin J 2005 Why thyroid cancer? Thyroid 15(4):303-304. (Pubitemid 40677398)
10. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP 1997 Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553-3562. (Pubitemid 27509336)
11. Mazzaferri EL 2009 What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? Oncology (Williston Park) 23:579-588.
12. Ito Y, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A 2005 Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 68:87-96.
13. Malandrino P, Pellegriti G, Attard M, Violi MA, Giordano C, Sciacca L, Regalbuto C, Squatrito S, Vigneri R 2013 Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab 98:1427-1434.
14. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A 2004 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 89:3713-3720. (Pubitemid 39071462)
15. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
16. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803. (Pubitemid 43997716)
17. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262. (Pubitemid 40896444)
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
19. Malandrino P, Scollo C, Marturano I, Russo M, Tavarelli M, Attard M, Richiusa P, Violi MA, Dardanoni G, Vigneri R, Pellegriti G 2013 Descriptive epidemiology of human thyroid cancer: experience from a regional registry and the "volcanic factor". Front Endocrinol (Lausanne) 4:65.
20. Pellegriti G, De Vathaire F, Scollo C, Attard M, Giordano C, Arena S, Dardanoni G, Frasca F, Malandrino P, Vermiglio F, Previtera DM, D'Azzo G, Trimarchi F, Vigneri R 2009 Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst 101:1575-1583.
21. Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, Moretti S, Nicolosi ML, Giani C, Cirello V, Avenia N, Rossi S,Vitti P, Pinchera A, EliseiR2012Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab 97:E1758-E1765.
22. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379. (Pubitemid 41759286)
23. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949.
24. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R 2008 BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15:191-205. (Pubitemid 351449739)
25. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-470; discussion 470-471. (Pubitemid 47312140)
26. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773.
27. Li C, Lee KC, Schneider EB, Zeiger MA 2012 BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97:4559-4570.
28. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco- Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V 2013 Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501.
29. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R 2006 Correlation between BRAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464. (Pubitemid 43886668)
30. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89-97.
31. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670. (Pubitemid 44402153)
32. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, Jang HC, Park SH, Park do J, Cho BY 2006 Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107:1831-1838. (Pubitemid 44582952)
33. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F 2012 The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390-4398.
34. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK 2005 The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf ) 63:588-593. (Pubitemid 41626756)
35. Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, Kim SW, Lee EN, Hong JC 2013 The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol 11:291.
36. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W 2009 Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 16:240-245.
37. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C 2007 BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid < or = 1 cm and their paired lymph node metastases. Cancer 110:1218-1226. (Pubitemid 47435591)
38. Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X, Gao M 2013 Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 20:2266-2273.
39. DeLellis RA 2004 Pathology & genetics: tumours of endocrine organs. Vol 8 IARC Press, Lyon, France.
40. Yu XM, Wan Y, Sippel RS, Chen H 2011 Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653-660.
41. Xing M 2010 Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93.
42. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M 2011 Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 71:3863-3871.
43. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97:517-524.
44. Xing M 2012 BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab 97:2295-2298.
45. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66:6521-6529. (Pubitemid 44085606)
46. Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE, Yip L 2012 BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol 20:47-52.
47. Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, Grant CS, Giordano TJ, Gauger PG, Doherty GM, Fahey TJ 3rd, Bishop J, Eshleman JR, Umbricht CB, Schneider EB, Zeiger MA 2013 Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab 98: 3702-3712.
48. Sellers M, Beenken S, Blankenship A, Soong SJ, Turbat- Herrera E, Urist M, Maddox W 1992 Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. Am J Surg 164:578-581.
49. Mazzaferri EL, Young RL 1981 Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511-518. (Pubitemid 11153883)
50. Cappola AR, Mandel SJ 2013 Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA 309:1529-1530.
51. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M 2012A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 97:2333-2340.
52. Dultz LA, Dhar S, Ogilvie JB, Heller KS, Bar-Sagi D, Patel KN 2013 Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer. Surgery 154:1239-44.